Cytokines and growth factors are important extracellular regulatory proteins. They exert their biological functions through binding to their cognate receptors on the cell surface and triggering intracellular signaling cascades. However, the intracellular signaling mechanisms of cytokines and growth factors are not well understood. Accumulating evidence has shown that protein phosphorylation and dephosphorylation carried out by protein kinases and protein phosphatases are fundamental biochemical events in intracellular signal transduction. SHP-2, a Src homology (SH) 2 domain-containing protein tyrosine phosphatase (PTP), is widely involved in a variety of signaling pathways triggered by cytokines and growth factors, including the MAP kinase, Jak-Stat, and PI3 kinase pathways. Recent studies have clearly demonstrated that this phosphatase plays an important role in transducing signals relayed from the cell surface to the nucleus, and is a critical intracellular regulator in cytokine and growth factor-induced cell survival, proliferation, and differentiation. D
Introduction
Cellular responses to a variety of extracellular stimuli including cytokines and growth factors are mediated by intracellular signaling pathways. A great deal of evidence has demonstrated that dysregulation of such signaling pathways initiated by extracellular factors causes malfunctioning of the targeted cells, and this may eventually lead to diseases. Many important cellular activities, such as cell survival, proliferation, and differentiation, are highly controlled by the intracellular signal transduction processes in which protein phosphorylation and dephosphorylation are central events [1 -3] . It is increasingly clear that such opposing biochemical reactions are carried out by protein kinases and protein phosphatases. Protein phosphorylation and dephosphorylation are closely related to the activities of signaling proteins and directly mediate protein -protein interactions. Thus, protein tyrosine phosphatases (PTPs), which dephosphorylate tyrosine phosphorylated signaling molecules, play equally important roles as protein tyrosine kinases (PTKs) in transducing signal flow and controlling cellular behavior. However, compared to PTKs, fewer PTPs have been identified, and there are limited studies regarding their signaling mechanisms. SHP-2, an SH2 domain-containing non-transmembrane PTP, is involved in signal transduction of a variety of cytokines and growth factors [4] [5] [6] [7] [8] and plays an important role in regulating cellular biological responses to external stimuli.
Structural basis
SHP-2, previously called SH-PTP2, SH-PTP3, PTP2C, PTP1D, and Syp, was identified independently by several groups as a cytosolic SH2 domain-containing PTP [4] [5] [6] [7] [8] . It is ubiquitously expressed in various tissues and cell types, sharing similar overall structure and high homology with SHP-1 phosphatase which is predominantly expressed in hematopoietic cells [9, 10] . Both phosphatases contain two tandem SH2 domains at the N-terminus and one tyrosine phosphatase domain at the C-terminus. The SH2 domain is a 100-amino-acid motif which mediates the binding of SHP-2 to phosphorylated tyrosine residues on other molecules, thus directing specific protein -protein interactions for this phosphatase [11] . Normally, SHP-2 phosphatase activity is repressed and mechanism of its activation is unclear. Earlier enzymological studies on SHP-1 phosphatase [12 -14] , together with the SHP-2 crystal structure studies [15] , indicate that only the N-terminal SH2 domain possesses auto-inhibitory influence on its catalytic activity. Deletion of the N-terminus of this phosphatase results in strong catalytic activation. Occupancy of the N-SH2 domain by phosphotyrosine residues leads to an increase in the catalytic activity of the SHP-2 phosphatase, possibly by inducing a conformational change in the enzyme [15, 16] . However, recent work of Lu et al. [17] argues that both SH2 domains can contribute to basal repression and consequent activation and implicates that the C-terminal tyrosine residues are also involved in SHP-2 activation.
Biochemical function in cytokine signaling
Accumulated biochemical data have shown that SHP-2 acts downstream of receptor and cytoplasmic tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Despite high homology to SHP-1 phosphatase, SHP-2 has completely different functions. Severe phenotypes observed in motheaten and motheaten viable mice harboring spontaneous mutations in the SHP-1 gene clearly indicate that SHP-2 cannot replace SHP-1 in most signaling pathways where they are both involved. Genetic analyses in Xenopus revealed that both the SH2 domains and the phosphatase domains contribute to signaling, and thus functional specificity of the SHP-2 and SHP-1 phosphatases [18, 19] . SHP-2 is widely expressed in various tissues and cell types and has been implicated in diverse signaling pathways including those initiated by growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), and cytokines as interleukin-3 (IL-3), granulocyte macrophage colony-stimulating factor (GM-CSF), IL-5, erythropoietin (EPO), IL-6, IL-1, and IL-2, as well as interferon and insulin [20, 21] . SHP-2 has compound signaling functions. It appears to be involved in a variety of signal transduction processes, such as the Ras-Raf-MAP kinase, JakStat, PI3 kinase, and NF-nB pathways. Even within a single signaling pathway, SHP-2 may act at multiple sites to participate in the signal transduction. For instance, SHP-2 directly interacts with growth factor and cytokine receptors, such as PDGF, EGF, stem cell factor (SCF), and EPO receptors, and becomes rapidly tyrosine phosphorylated upon ligand binding. It can also interact with a variety of signaling intermediates such as Grb2, FRS-2, Jak2, p85 subunit of PI3 kinase, IRS-1, and Gab1 and 2. As a PTP, SHP-2 is believed to function by dephosphorylating its associated signaling molecules, thus diminishing local signals. However, the ultimate effect of SHP-2 in most signaling pathways is to enhance the signal transduction.
In most circumstances, SHP-2 plays a positive role in transducing signals relayed from receptor PTKs [18,22 -25] . Previous biochemical evidence has demonstrated that the SHP-2 enzymatic activity is required for its function in signal transduction [22, 26] . Cysteine (Cys) at amino acid residue 459 has been identified as critical for its phosphatase activity. While the replacement of cysteine with serine (Ser) at this site completely abolishes its enzymatic activity, the capacity for this mutant molecule to bind to other signaling intermediates via its SH2 domains remains unaltered. It thus functions as a dominant negative molecule over the endogenous wild-type SHP-2. Using this dominant negative mutant, SHP-2 has been reported, by a number of studies, to positively regulate the signaling pathways initiated by insulin, EGF, PDGF, and fibroblast growth factor (FGF) [22, 23, [27] [28] [29] [30] . Overexpression of this mutant protein has been shown to block the signaling functions of endogenous SHP-2 in both in vitro and in vivo models. For instance, introduction of the catalytically inert SHP-2 molecule markedly inhibited activation of Erk kinase in response to EGF, insulin, and fibronectin stimulation [22, 23, [27] [28] [29] [30] . Although the precise biochemical basis for such positive regulation by this phosphatase in the Erk pathway remains unclear, it appears that SHP-2 acts in association with the Grb2 -Sos complex. Biochemical studies on csw, the Drosophila homologue of SHP-2, revealed that SHP-2 may function at a parallel level or upstream of Ras in the MAP kinase pathway [31] . This notion is subsequently supported by the results obtained from mammalian cells, as overexpression of catalytically inactive SHP-2 in 293 cells significantly inhibits Erk kinase activation and subsequent Elk-1 transactivation following EGF stimulation. However, the inactive SHP-2 fails to inhibit Elk-1 transactivation by activated Ras. Additionally, it has been suggested that SHP-2 phosphatase also functions as an adaptor protein [32 -34] . Our recent studies suggest that SHP-2 promotes IL-3-induced Jak2 activation in a catalytic-independent manner, and the conformational changes induced by the physical association between SHP-2 and Jak2 may contribute to the positive role of this phosphatase in this respect (unpublished data).
SHP-2 does play a negative role in certain intracellular signaling processes. Thus, it may have dual functions in cytokine and growth factor signal transduction. SHP-2 negatively regulates the Jak-Stat signaling pathway initiated by interferon-a and -g. As a consequence, mutant cells with a deletion mutation of SHP-2 are more sensitive to cytotoxicity of interferons, and activation of downstream Stat2 and Stat1 is elevated [35] . Another prominent example is that SHP-2 has been found to diminish the signal relayed from gp130. We and others have demonstrated that SHP-2 negatively regulates gp130 signaling triggered by leukemia inhibitory factor, ciliary neurotrophic factor, and IL-6 [36 -40] . Moreover, the recent knock-in mouse model, in which the endogenous gp130 has been replaced with a human gp130 Y759F (equivalent to residue 757 in mouse) mutant that does not bind to SHP-2, displayed lymphoadenopathy, splenomegaly, and an enhanced acute-phase immune response [40] . However, since the data supporting the negative regulatory role for SHP-2 in this mouse model were based on enhanced gp130-dependent signaling when Y757 on gp130, a pivotal binding site for SHP-2, is mutated to phenylalanine, it remains to be resolved whether these phenotypes were really mediated by SHP-2. A more recent report demonstrated that the Y757 was also the recognition site for suppressor of cytokine signaling-3 (SOCS-3), a putative SH2 domain containing cytokine signaling suppressor [41] . SOCS-3 and SHP-2 may compete for binding to this site, and SHP-2 functions to block the effects of SOCS-3 in the gp130 pathway [41] .
SHP-2 is also highly expressed in hematopoietic cells, and has been indicated to be involved in hematopoietic cytokine signal transduction [42 -44] . It has been demonstrated that SHP-2 participates in the signal transduction from IL-3, EPO, SCF, GM-CSF, and IL-5. However, compared to SHP-1 phosphatase, understanding of the physiological and biochemical functions of SHP-2 in hematopoietic cell signaling is limited. A potential role for SHP-2 phosphatase in hematopoietic cytokine signaling is indicated by indirect evidence based on receptor-mediated changes in SHP-2 tyrosine phosphorylation and/or its association with receptors or other signaling intermediates. Unfortunately, the cellular significance of SHP-2 involvement in these cytokine signaling pathways remains to be further elucidated. This could be achieved through the signal transduction studies on the mutant hematopoietic cell lines lacking this phosphatase. Thus, direct evidence showing SHP-2 biological functions and the biochemical significance of its enzymatic activity remains to be obtained.
Identification of the downstream targets or substrates of SHP-2 will help to elucidate the biochemical basis of SHP-2 activity in cytokine signal transduction. To date, several such molecules have been identified, such as SHPS-1 [45] , PZR [46] , and the newly characterized pleckstrin homology domain-containing scaffolding or docking proteins, Gab1 [47] and Gab2 [48 -50] . Tyrosine phosphorylation responses of these potential substrates in catalytically inactive SHP-2 overexpressing cells stimulated by cytokines are significantly elevated. In fact, Gab2 was originally identified to be a major SHP-2-binding protein in IL-3-stimulated hematopoietic cells [51] . Subsequently, the strong association between SHP-2 and Gab2 was further demonstrated to be induced by thrombopoietin (TPO) and EPO as well as TCR engagement [50] . In addition, the SHP-2/Gab2 complex is also assembled in hematopoietic cells following h1 integrin cross-linking [52] . Although the SHP-1/Gab2 association was not detected in the earlier studies [51] , our [52] and others' [53] recent results have showed that SHP-1 also associates with Gab2. However, unlike the SHP-2/Gab2 association, SHP-1 and Gab2 are associated through the C-terminal SH2 domain in a constitutive manner. Thus, both SHP-2 and SHP-1 phosphatases anchor to the same docking protein Gab2, which may serve as a linker for the functional interaction between these two enzymes. Even though the aforementioned potential targets showed strong association with SHP-2, it appears that they do not represent the authentic substrates for this phosphatase. None of them can explain the positive regulation by SHP-2 phosphatase in cytokine signaling pathways.
Biological function in cellular response to cytokine stimulation
An extensive distribution of SHP-2 phosphatase indicates that it might have a wide range of physiological functions. Recent data from SHP-2 gene knock-out mice have clearly suggested this notion. Mice homozygous for a SHP-2 Nterminal deletion (amino acids 46 -110) mutation exhibit embryonic lethality. Homozygous mutants die at midgestation with multiple developmental defects in mesodermal patterning and body organization [54, 55] and this is in agreement with previous genetic analysis in Xenopus [19] . A similar requirement for SHP-2 in Xenopus development was found to be attributed to its positive role in basic FGF signaling [19] . Chimeric mice generated from homozygous mutant embryonic stem (ES) cells with the deletion mutation of SHP-2 die at various stages, depending on the contribution from the mutant cells [56] . This strategy has proven to be an efficient alternative approach for further defining the physiological functions that are masked due to the early embryonic lethality of the mutant mice. Several interesting phenotypes were observed in the chimeric mice containing SHP-2 mutant cells, such as abnormal development of the skeleton and limbs [56, 57] and 50% of the chimeric mice had an open eyelid phenotype. As defective eyelid development is a typical phenotype of EGF receptor knock-out mice, this observation suggests that SHP-2 is required for the in vivo action of EGF. Further genetic analyses showed that a SHP-2 heterozygous mutation dominantly enhanced the phenotypes of EGF receptor weak allele (wa-2/wa-2) toward EGF receptor null mutant mice. Reducing SHP-2 protein level by half significantly diminished further the EGF signaling on the background of the EGF receptor point mutation [58] . Subsequently, Chen et al. [59] showed that the incidence and severity of the defective cardiac semilunar valvulogenesis was enhanced in wa-2/wa-2 mice with a heterozygous mutation of SHP-2, further indicating a functional requirement for SHP-2 in EGF signaling.
In vitro studies have also revealed that SHP-2 plays critical roles in regulating a number of cellular activities. ES cells are totipotent embryonic stem cells, which can be induced to differentiate into a variety of cell lineages, including hematopoietic cells, cardiomyocytes, and even neuronocytes. SHP-2 deletion mutation in such stem cells severely decreased erythroid lineage differentiation, and myeloid lineage development was completely blocked [60] . Consistent with the in vitro observations, in vivo hematopoietic progenitor development of mutant ES cell origin in the bone marrow and fetal liver from the chimeric mice generated from homozygous mutant ES cells was undetectable [56] . Further hematopoietic progenitor analysis of the yolk sac, the earliest embryonic hematopoietic tissue, demonstrated that hematopoietic activity in SHP-2 mutant yolk sac was dramatically decreased, suggesting that the SHP-2 mutation blocks hematopoietic development at the primitive hematopoiesis stage. Moreover, SHP-2 is also required for lymphoid lineage development, as SHP-2 mutation completely blocked T and B lymphocyte development of the mutant ES cells in SHP-2 À / À /RAG-2 À / À chimeric mice. Thy + T cells and B220 + B cells derived from the mutant ES cells were not detected, suggesting that T and B lymphocyte development was blocked at the Pro-T and Pro-B stages [61] . It appears that these developmental defects occur at very early stages in the differentiation process of ES cells. Indeed, SHP-2 mutation significantly reduces ES cell differentiation potential [37, 39] . The in vitro differentiation of other lineages, including cardiomyocytes and fibroblasts from mutant ES cells, was also dramatically decreased. Since hematopoietic cell development and other in vivo cellular processes are tightly regulated by extracellular growth factors and cytokines, all of these data taken together strongly suggest an indispensable role for SHP-2 phosphatase in the signal transduction of some growth factors and cytokines.
In contrast to SHP-2 phosphatase, the related SHP-1 phosphatase negatively regulates cytokine signaling [62 -65] . Functional studies on SHP-1 phosphatase has been considerably facilitated by analyses of motheaten (me/me) and viable motheaten (me v /me v ) mice containing spontaneous mutations in the coding region for the N-terminal SH2 domain and the catalytic domain of SHP-1, respectively [66, 67] . Homozygous mutants have obvious hematological abnormalities. Both me/me and me v /me v mice develop systemic autoimmune disease and die after approximately 3 and 9 weeks, respectively [68] . High levels of immunoglobulins, particularly autoantibodies in peripheral blood, excessive erythropoiesis in spleen, and dramatically enhanced cell growth in response to hematopoietic growth factor stimulation suggest a primarily negative regulatory role for this phosphatase in hematopoietic development and function. Consistent with this, it has been found that SHP-1 attenuates signals emanating from receptors for EPO, IL-3, GM-CSF, and M-CSF, and mediates inhibitory signals triggered by NK cell inhibitory receptor, TCR, BCR, CD22, and CD72 [62 -64,69 -71] . Taken together, these findings suggest that SHP-2 and the related SHP-1 phosphatase have opposing functions in regulating cytokine signaling, despite sharing high homology. Indeed, this view is strongly supported by our recent hematopoietic analyses on the SHP-2/SHP-1 double mutant mice. Defective primitive hematopoiesis caused by the SHP-2 mutation was partially rescued by an additional SHP-1 mutation [61] . More recently, we generated SHP-2, SHP-1 and SHP-2/SHP-1 double mutant primitive hematopoietic cell lines. Preliminary studies using these cell lines have suggested that SHP-2 plays a dominant role in determining IL-3-induced hematopoietic cell responses, overriding the function of SHP-1. Further biochemical analyses revealed that SHP-2 was required for IL-3-induced Jak2 kinase activation, while SHP-1 negatively regulates this process (unpublished data).
Perspectives
It is clear that SHP-2 tyrosine phosphatase plays critical roles in regulating a number of cytokine signals and mediates a variety of cellular biological processes. Nevertheless, many questions regarding the biochemical basis for its signaling functions still remain to be resolved. Several prominent questions are: Why does SHP-2, a protein tyrosine phosphatase, in most circumstances, play a positive role in transducing signal from cytokine receptors and what is the direct biochemical significance of its phosphatase activity? Identification of its real in vivo substrates would shed light on its biochemical function. Importantly, several recent reports have indicated a clinical relevance of SHP-2 phosphatase to some human diseases such as Noonan syndrome [72] , neutropenia (Kostmann's syndrome) [73] and diabetes [6, 74] , further emphasizing the importance of studies on the biochemical functions of this enzyme in cytokine and growth factor signal transduction. Understanding the mechanisms of SHP-2 action may provide novel insights into the regulation of intracellular signaling network and may lead to novel molecular therapeutic approaches for certain diseases.
